Close Menu

Editor's Pick

The NCI will launch a lab network to provide researchers with centralized assays for conducting genomic and pharmacodynamic analysis for molecularly targeted drugs.

A private payor survey by ClearView Healthcare Partners found that medical directors viewed CMS's decision with caution; half had no plans to align commercial plan coverage.

Pages